Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04299906
Other study ID # FCRE-191127
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 17, 2021
Est. completion date December 30, 2024

Study information

Verified date November 2023
Source FCRE (Foundation for Cardiovascular Research and Education)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical investigation is to evaluate, in a controlled setting, the long-term (up to 12 months) safety and efficacy of the Solaris Vascular Stent Graft (Scitech) in clinical settings when used according to the indications of the IFU.


Other known NCT identifiers
  • NCT04545281

Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date December 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Corresponding to the IFU indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions. - Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator) - Patient presenting a score from 2 to 5 following Rutherford classification - Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study - Patient is >18 years old - Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study - The target lesion is either a modified TASC-II class A, B, C or D lesion. - The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation - There is angiographic evidence of a patent Common and Deep Femoral Artery Exclusion Criteria: - PTA is technically not possible (not feasible to access the lesion or a defect with the guidewire or balloon catheter) - Presence of an aneurysm immediately adjacent to the site of stent implantation - Stenosis distal to the site of stent implantation - Lesions in or adjacent to essential collaterals(s) - Lesions in locations subject to external compression - Heavily calcified lesions resistant to PTA - Patients with diffuse distal disease resulting in poor stent outflow - Patients with a history of coagulation disorders - Patients with aspirin allergy or bleeding complications and patients unable or unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to anticoagulant/antiplatelet therapy - Fresh thrombus formation - Patients with known hypersensitivity to the stent material (L605) and/or PTFE - The target lesion is either a modified TASC-II class B or D lesion with aortic or common femoral lesion involvement. - Previously implanted stent(s) at the same lesion site - Reference segment diameter is not suitable for the available stent design - Untreatable lesion located at the distal outflow arteries - Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure - Patients refusing treatment - Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated - Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site - Perforation at the angioplasty site evidenced by extravasation of contrast medium - Patients with a history of prior life-threatening contrast medium reaction - Patients with uncorrected bleeding disorders - Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding - Life expectancy of less than twelve months - Any planned surgical intervention/procedure within 30 days of the study procedure - Any patient considered to be hemodynamically unstable at onset of procedure - Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.

Study Design


Intervention

Device:
Solaris Vascular Stent Graft
Solaris Vascular Stent Graft for treatment of Iliac Lesions

Locations

Country Name City State
Germany Hospital Hochsauerland Arnsberg
Germany Saarland University Medical Center Homburg
Germany University Hospital Leipzig Leipzig
Germany St. Franziskus Hospital Münster
Germany University Hospital Münster Münster
Germany Hospital Oldenburg Oldenburg
Italy Azienda Ospedaliera di Perugia Perugia
Italy Fondazione Policlinico Gemelli Rom
Netherlands MCL Leeuwarden Leeuwarden
Netherlands St. Antonius Hospital Nieuwegein

Sponsors (3)

Lead Sponsor Collaborator
Dr. Sabrina Overhagen FCRE (Foundation for Cardiovascular Research and Education), Scitech Produtos Medicos Ltda

Countries where clinical trial is conducted

Germany,  Italy,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Patency Rate at 12 month follow-up 12 months post-op
Secondary Primary Patency Rate at 1- and 6 month follow-up 1 monthand 6 months post-op
Secondary Stent Graft Occlusion Rate at pre-discharge, 1-, 6-, and 12-month follow-up 1day, 1 month, 6 month and 12 month post-op
Secondary Ankle-Brachial Index at 1-, 6- and 12-month follow-up compared with baseline ABI 1-, 6- and 12-month post-op
Secondary Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee 1-, 6- and 12-month post-op
Secondary Performance success rate at baseline defined as a composite of (a) successful in sealing acute perforation or rupture; (b) successful in treating aneurysm and fistulae ; (c) restoration of blood flow during procedure
Secondary in-stent restenosis rate at 1-, 6- and 12-month post-op 1-, 6-, 12-month post-op
Secondary Freedom from Target Lesion Revascularization at 1-, 6- and 12-month post-op defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge 1-, 6- and 12-month post-op
Secondary Serious Adverse Events (SAE's) until 12-month post-op within 12-months post-op
Secondary Technical success rate defined as the ability to achieve final residual angiographic stenosis no greater than 30% during procedure
Secondary Clinical success at follow-up defined as an improvement of Rutheford Classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification 1-, 6- and 12-month post-op
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1